Page last updated: 2024-12-07
cui xing ning
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
cui xing ning: RN given is for parent compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 132200 |
MeSH ID | M0106920 |
Synonyms (8)
Synonym |
---|
carbaindoline |
5-(1,3,3-trimethylindoline)-n,n-dimethylcarbamate |
5-(1,3,3-trimethylindolinyl)-n,n-dimethylcarbamate |
139052-05-4 |
carbamic acid, dimethyl-, 2,3-dihydro-1,3,3-trimethyl-1h-indol-5-yl ester, monohydrochloride |
cui xing ning |
DTXSID40160879 |
(1,3,3-trimethyl-2h-indol-5-yl) n,n-dimethylcarbamate;hydrochloride |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
"kg-1) shifted the dose-response curve of xylazine induced sedation to the right, hemicholinum-3 (3 micrograms icv), which inhibits the synthesis of acetylcholine, shifted the dose-response curve to the left." | ( [Antagonistic effects of cholinergic drugs on xylazine induced sedation]. Ding, RG; Huang, SJ; Yang, JS, 1993) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 4 (80.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |